Settlement in Yarrington v. Solvay Pharmaceuticals, Inc.

Today, Solvay Pharmaceuticals, Inc. entered into a Settlement Agreement with Plaintiffs in Yarrington v. Solvay Pharmaceuticals, Inc., which alleges that Defendant Solvay Pharmaceuticals, Inc. (“Solvay”) violated state unfair competition and false and deceptive advertising laws in marketing Estratest and Estratest H.S., prescription hormone therapy drugs.The Settlement included anyone who purchased Estratest or Estratest H.S. in any state, other than California, since March 8, 1998.  Pursuant to the Settlement Agreement, which was granted final approval by the U.S. District Court of Minnesota (Hon. Richard H. Kyle) on March 16, 2010, Solvay has agreed to pay 16.5 million to Settlement Class Members.  In approving the Settlement, Judge Kyle recognized that Settlement Class Counsel "exhibited a great deal of skill in advocating on behalf of their clients" and "exhibited diligence and efficiency throughout the litigation, resulting in a favorable result for the Class."  Gustafson Gluek PLLC and Lieff Cabraser Heimann & Bernstein LLP are Settlement Class Counsel.  Notably, Settlement Class Members who timely filed valid claims received 100% of their claimed damages - a percentage almost unheard of in class action litigation.To obtain further information, please visit:www.EstratestSettlement.com